Home > Research > Publications & Outputs > Gene therapy-mediated enhancement of protective...

Electronic data

  • Owens et al BRES_author accepted ms

    Rights statement: This is the author’s version of a work that was accepted for publication in Brain Research. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Brain Research, 1753, 2021 DOI: 10.1016/j.brainres.2020.147264

    Accepted author manuscript, 1.3 MB, PDF document

    Available under license: CC BY-NC-ND: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

Links

Text available via DOI:

View graph of relations

Gene therapy-mediated enhancement of protective protein expression for the treatment of Alzheimer's disease

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Gene therapy-mediated enhancement of protective protein expression for the treatment of Alzheimer's disease. / Owens, Lauren; Benedetto, Alex; Dawson, Neil; Gaffney, Christopher; Parkin, Edward.

In: Brain Research, Vol. 1753, 147264, 15.02.2021.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{1383d2184a6e48bdbb02b4a4e7dcd7f5,
title = "Gene therapy-mediated enhancement of protective protein expression for the treatment of Alzheimer's disease",
abstract = "Alzheimer{\textquoteright}s disease (AD) is the leading form of dementia but lacks curative treatments. Current understanding of AD aetiology attributes the development of the disease to the misfolding of two proteins; amyloid-β (Aβ) and hyperphosphorylated tau, with their pathological accumulation leading to concomitant oxidative stress, neuroinflammation, and neuronal death. These processes are regulated at multiple levels to maintain homeostasis and avert disease. However, many of the relevant regulatory proteins appear to be downregulated in the AD-afflicted brain. Enhancement/restoration of these {\textquoteleft}protective{\textquoteright} proteins, therefore, represents an attractive therapeutic avenue. Gene therapy is a desirable means of achieving this because it is not associated with the side-effects linked to systemic protein administration, and sustained protein expression virtually eliminates compliance issues. The current article represents a focused and succinct review of the better established {\textquoteleft}protective{\textquoteright} protein targets for gene therapy enhancement/restoration rather than being designed as an exhaustive review incorporating less validated protein subjects. In addition, we will discuss how the risks associated with uncontrolled or irreversible gene expression might be mitigated through combining neuronal-specific promoters, inducible expression systems and localised injections. Whilst many of the gene therapy targets reviewed herein are yet to enter clinical trials, preclinical testing has thus far demonstrated encouraging potential for the gene therapy-based treatment of AD.",
keywords = "Alzheimer{\textquoteright}s disease, Gene therapy, Protective proteins, Amyloid beta, Tau",
author = "Lauren Owens and Alex Benedetto and Neil Dawson and Christopher Gaffney and Edward Parkin",
note = "This is the author{\textquoteright}s version of a work that was accepted for publication in Brain Research. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Brain Research, 1753, 2021 DOI: 10.1016/j.brainres.2020.147264",
year = "2021",
month = feb,
day = "15",
doi = "10.1016/j.brainres.2020.147264",
language = "English",
volume = "1753",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Gene therapy-mediated enhancement of protective protein expression for the treatment of Alzheimer's disease

AU - Owens, Lauren

AU - Benedetto, Alex

AU - Dawson, Neil

AU - Gaffney, Christopher

AU - Parkin, Edward

N1 - This is the author’s version of a work that was accepted for publication in Brain Research. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Brain Research, 1753, 2021 DOI: 10.1016/j.brainres.2020.147264

PY - 2021/2/15

Y1 - 2021/2/15

N2 - Alzheimer’s disease (AD) is the leading form of dementia but lacks curative treatments. Current understanding of AD aetiology attributes the development of the disease to the misfolding of two proteins; amyloid-β (Aβ) and hyperphosphorylated tau, with their pathological accumulation leading to concomitant oxidative stress, neuroinflammation, and neuronal death. These processes are regulated at multiple levels to maintain homeostasis and avert disease. However, many of the relevant regulatory proteins appear to be downregulated in the AD-afflicted brain. Enhancement/restoration of these ‘protective’ proteins, therefore, represents an attractive therapeutic avenue. Gene therapy is a desirable means of achieving this because it is not associated with the side-effects linked to systemic protein administration, and sustained protein expression virtually eliminates compliance issues. The current article represents a focused and succinct review of the better established ‘protective’ protein targets for gene therapy enhancement/restoration rather than being designed as an exhaustive review incorporating less validated protein subjects. In addition, we will discuss how the risks associated with uncontrolled or irreversible gene expression might be mitigated through combining neuronal-specific promoters, inducible expression systems and localised injections. Whilst many of the gene therapy targets reviewed herein are yet to enter clinical trials, preclinical testing has thus far demonstrated encouraging potential for the gene therapy-based treatment of AD.

AB - Alzheimer’s disease (AD) is the leading form of dementia but lacks curative treatments. Current understanding of AD aetiology attributes the development of the disease to the misfolding of two proteins; amyloid-β (Aβ) and hyperphosphorylated tau, with their pathological accumulation leading to concomitant oxidative stress, neuroinflammation, and neuronal death. These processes are regulated at multiple levels to maintain homeostasis and avert disease. However, many of the relevant regulatory proteins appear to be downregulated in the AD-afflicted brain. Enhancement/restoration of these ‘protective’ proteins, therefore, represents an attractive therapeutic avenue. Gene therapy is a desirable means of achieving this because it is not associated with the side-effects linked to systemic protein administration, and sustained protein expression virtually eliminates compliance issues. The current article represents a focused and succinct review of the better established ‘protective’ protein targets for gene therapy enhancement/restoration rather than being designed as an exhaustive review incorporating less validated protein subjects. In addition, we will discuss how the risks associated with uncontrolled or irreversible gene expression might be mitigated through combining neuronal-specific promoters, inducible expression systems and localised injections. Whilst many of the gene therapy targets reviewed herein are yet to enter clinical trials, preclinical testing has thus far demonstrated encouraging potential for the gene therapy-based treatment of AD.

KW - Alzheimer’s disease

KW - Gene therapy

KW - Protective proteins

KW - Amyloid beta

KW - Tau

U2 - 10.1016/j.brainres.2020.147264

DO - 10.1016/j.brainres.2020.147264

M3 - Journal article

VL - 1753

JO - Brain Research

JF - Brain Research

SN - 0006-8993

M1 - 147264

ER -